Skip to main content
Skip to "About this site"
Canada.ca
Services
Departments
Language selection
Français
Search and menus
Search and menus
Patented Medicine Prices Review Board
Search
Search website
Search
[ENGLISH_LABEL_SITEMENU]
Legislation
Act and Regulations
Compendium of Policies, Guidelines and Procedures
Rules of Practice and Procedures for Hearings
Regulatory Management
Regulating Prices
Regulatory Process
Scientific Review
Price Review
Investigations
Advance Ruling Certificates
VCUs
Hearings
The Hearing Process
Status of Ongoing Proceedings
Decisions and Orders
Rules of Practice and Procedures for Hearings
Reporting
Reports and Trends
Pharmaceutical Trends
Annual Reports
NPDUIS
About NPDUIS
Analytical Studies
Research Agenda
NPDUIS Advisory Committee
You are here:
Home
2006 Formulas for Verification of Foreign Patented Drug Prices
2006 Formulas for Verification of Foreign Patented Drug Prices
France
FP given in
SEMPEX
in euros
FP (reported in the formulary under column "Px–Achat") is directly comparable to the PP reported by the patentee
The WP is derived as follows:
If: FP ≤ 22.90
WP = FP/1.1030
22.90 < FP ≤ 150.00
WP = 20.76 + (FP − 22.90)/1.06
FP > 150.00
WP = 140.66 + (FP − 150)/1.02
No price comparable to the HP reported by the patentee
Germany
FP given in
Rote Liste
in euros
FP includes 16% VAT; FPN = FP/1.16
Prescription Drugs
PP = (FPN – 8.10)/1.03
The WP is derived as follows:
If: 0 < PP ≤ 3.45
WP = PP/1.15
3.45 < PP ≤ 4.19
WP = PP − 0.45
4.19 < PP ≤ 5.60
WP = PP/1.12
5.60 < PP ≤ 7.26
WP = PP − 0.60
7.26 < PP ≤ 9.81
WP = PP/1.09
9.81 < PP ≤ 12.37
WP = PP − 0.81
12.37 < PP ≤ 24.61
WP = PP/1.07
24.61 < PP ≤ 28.43
WP = PP − 1.61
28.43 < PP ≤ 1,272.00
WP = PP/1.06
PP > 1,272.00
WP = PP − 72
No price comparable to the HP reported by the patentee
OTC Drugs
The PP is derived as follows:
If: FPN ≤ 2.04
PP = FPN/1.68
2.04 < FPN ≤ 2.16
PP = FPN − 0.8296
2.16 < FPN ≤ 6.28
PP = FPN/1.62
6.28 < FPN ≤ 6.62
PP = FPN − 2.4056
6.62 < FPN ≤ 11.4
PP = FPN/1.57
11.40 < FPN ≤ 12.8
PP = FPN − 4.161
12.80 < FPN ≤ 17.90
PP = FPN/1.48
17.90 < FPN ≤ 19.30
PP = FPN − 5.8272
19.30 < FPN ≤ 27.7
PP = FPN/1.43
27.70 < FPN ≤ 30.90
PP = FPN − 8.3506
30.90 < FPN ≤ 42.40
PP = FPN/1.37
42.40 < FPN ≤ 49.20
PP = FPN − 10.78
49.20 < FPN ≤ 707.08
PP = FPN/1.303
FPN > 707.08
PP = (FPN − 118.24)/1.08263
The WP is derived as follows:
If: 0 < PP ≤ 1.01
WP = PP/1.21
1.01 < PP ≤ 1.05
WP = PP − 0.1764
1.05 < PP ≤ 2.04
WP = PP/1.20
2.04 < PP ≤ 2.08
WP = PP − 0.34
2.08 < PP ≤ 3.05
WP = PP/1.195
3.05 < PP ≤ 3.12
WP = PP − 0.4992
3.12 < PP ≤ 4.34
WP = PP/1.19
4.34 < PP ≤ 4.44
WP = PP − 1.69
4.44 < PP ≤ 7.14
WP = PP/1.185
7.14 < PP ≤ 7.31
WP = PP − 1.11555
7.31 < PP ≤ 10.70
WP = PP/1.18
10.70 < PP ≤ 12.60
WP = PP − 1.638
12.60 < PP ≤ 51.10
WP = PP/1.15
51.10 < PP ≤ 62.20
WP = PP − 6.67
62.20 < PP ≤ 766.93
WP = PP/1.12
PP > 766.93
WP = (PP − 61.63)/1.03
No price comparable to the HP reported by the patentee
Italy
FP given in
l'Informatore Farmaceutico
in euros
FP includes a 10% VAT; FPN = FP/1.10
PP = FPN x 0.733
WP = FPN x 0.6665
No price comparable to the HP reported by patentee
Sweden
FP given in
Prislista
in Swedish kronas
The PP is derived as follows:
If: FP ≤ 121.25
PP = (FP − 31.25)/1.20
121.25 < FP ≤ 353.0
PP = (FP − 44.00)/1.03
353.0 < FP ≤ 6,167.0
PP = (FP − 47.00)/1.02
FP > 6,167.0
PP = FP − 167.0
The WP is derived as follows:
If: FP ≤ 121.25
WP = (FP − 31.25)/(1.20 x 1.032)
121.25 < FP ≤ 353.00
WP = (FP − 44.00)/(1.03 x 1.032)
353.0 < FP ≤ 6,167.0
WP = (FP − 47.00)/(1.02 x 1.032)
FP > 6,167.0
WP = (FP − 167.0)/1.032
No price comparable to the HP reported by patentee
Switzerland
FP given in Switzerland formulary (
Medwin
website) in Swiss francs
FP is directly comparable to the WP reported by the patentee
No prices comparable to the HP and the PP reported by patentee
United Kingdom
FP given in the
Monthly Index of Medical Specialties
(MIMS) in UK pounds
FP is directly comparable to the PP reported by the patentee
WP = FP x 0.875
No price comparable to HP reported by patentee
United States
No regulated mark–ups
Prices given in US dollars
The
Direct Price
is directly comparable to the PP and/or HP reported by the patentee
The
Wholesale Acquisition Cost
(
WAC
) price is directly comparable to the WP reported by the patentee
The
Federal Supply Schedule
(
FSS
) price has been required by the PMPRB since 1998 and included in IPC tests since 2000
Date modified:
2015-11-09
Secondary menu